Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next‐Generation Sequencing in Detecting Actionable Driver Mutations in Anti‐EGFR Naive Metastatic Colorectal Cancer

BACKGROUND: Direct comparisons between Guardant360 (G360) circulating tumor DNA (ctDNA) and FoundationOne (F1) tumor biopsy genomic profiling in metastatic colorectal cancer (mCRC) are limited. We aim to assess the concordance across overlapping genes tested in both F1 and G360 in patients with mCRC...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Gupta, Rohan, Othman, Tamer, Chen, Chen, Sandhu, Jaideep, Ouyang, Ching, Fakih, Marwan
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2019
Témata:
Gastrointestinal Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066697/
https://ncbi.nlm.nih.gov/pubmed/32162812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0441
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky